Awards Badges AWIE2017 Shortlisted Best Conference Development
AIPES was nominated for the 6th Association Awards, in the Conference Development category for the 2016 AIPES Symposium. The congress and award took place in Vienna and the AIPES Symposium 2016 arrived in second place.


Recent publications:

Capture d'écran 2017 04 17 à 14 37 00
Innovation Focus - Hybrid Imaging
Over the past few years, Nuclear Medicine (NM) has undergone impressive growth with the development of equipment and radiopharmaceutical products. These developments paved the way for personalized and targeted medicine by offering practical solutions, especially in oncology, neurology, and cardiology.
[read more ]

Cyclotrons for Medical Radionuclide Production
Pictorial view Cyclotrons

SPECT CT in Clinica Use
Pictorial view SPECT CT in Clinical Use

Positron Emission Tomography using 18F labelled glucose.
pictorial view of NM

SPECT and Planar Scintigraphy.
pictorial SPECT

Vectorized or Metabolic Radiotherapy.
Pictorial View Therapy

New Photon Detection Technologies in Nuclear Medicine.
Novel detector front

White Paper on SPECT and SPECT CT Imaging An introduction to Mainstay Diagnostic Testing in Non-invasive Medicine
white paper on SPECT and SPECT CT Imaging

© AIPES eeig., 2012- All rights reserved for all countries


VaudevilleSymposium: “Nuclear Medicine in Cancer Management: Improving Efficacy and Reducing Costs" Brussels, Wednesday 16 September 2015 Theâtre du Vaudeville

Solvay LibrarySymposium: “Molecular Imaging: Nuclear Medicine Innovations driving Economic Benefits” – Brussels, Wednesday 7 May 2014, The Solvay Library

The main messages from the conference are published in an EJNMMI editorial article signed by the speakers and moderators. The article is open access and can be downloaded from the EJNMMI website

michael kuhnConference: "LATEST DEVELOPMENTS IN HYBRID IMAGING - Current and Future Hybrid Imaging Technology" - Dr Ing. Michael H. Kuhn, Chief Strategy & Innovation Office Philips Healthcare – Brussels, 22 May 2013.

Hybrid Imaging provides complementary medical imaging information acquired in a workflow-efficient manner. It supports the paradigm of quantitative imaging as a biomarker. The first imaging modality referred to as “hybrid” was PET-CT. The technological development of this hybrid system was driven by the desire to obtain better quantitative information, i.e. patient outcome benefits, but its wide spread adoption was accelerated by workflow efficiency benefits. The recent new hybrid modality is MR-PET, which is being adopted at a surprising rate in spite of its high price because of assumed clinical benefits from superior soft tissue contrast from MR over CT, but also based on the assumption that the functional imaging capabilities of MRI, together with the highly sensitive metabolic imaging capabilities of PET, will enable new applications. On the horizon, there is a completely new hybrid imaging modality: the combination of Magnetic Particle Imaging (MPI) with either CT or MRI for anatomical reference imaging.

Juhani Knuuti 1Conference: "Hybrid Imaging in Cardiology" - Juhani Knuuti, MD, PhD, Professor, Director, Turku PET Centre University of Turku and Turku University Hospital, Turku, Finland – Brussels, 22 May 2013.

Cardiac hybrid imaging combines different modalities in order to obtain complementary anatomical and functional information in a single imaging study. Morphological imaging with CT and MR has benefited from the improvement of spatial and temporal resolution, which revitalized especially the role of CT in diagnostic imaging. Multi-slice CT imaging has become an important tool to detect coronary artery disease. At the same time, functional imaging has expanded its role in the clinical assessment of severity and extent of disease processes with documented prognostic value. Magnetic resonance imaging as well as tracer techniques using SPECT and PET has added an important new dimension to the functional characterization of pathophysiological processes by providing regional information on perfusion, metabolism and cell integrity. PET/CT, SPECT/CT and more recently PET/MRI systems have become commercially available and increasingly used also in cardiac imaging for both small animals for research purposes and humans for clinical research and routine. Coronary CT angiography (CTA) and myocardial perfusion imaging with positron emission tomography (PET) are established non-invasive modalities for the diagnosis of coronary artery disease (CAD). Hybrid PET-CT is a promising tool for evaluation of CAD allowing detection of the coronary atherosclerotic plaques and their consequences on myocardial blood flow in a single study. This appears to offer superior diagnostic accuracy for the detection of flow-limiting stenosis in patients with intermediate probability of CAD. Recently also noninvasive imaging of coronary vulnerable plaques has become feasible using hybrid systems. The combination of PET and MRI is also promising for cardiac applications. PET provides functional characterization of metabolism and cell integrity and when combined with contrast enhanced cardiac MRI, unique information about myocardial viability and inflammatory cardiac diseases can be expected. Furthermore, new imaging targets are under investigations and specific receptor families as well as cell surface proteins have been developed as targets for various imaging approaches and these specific non-invasive imaging methods are likely used for diagnosis and therapy guidance. These developments are believed to be the main players for the success of personalised medicine but also help in drug discovery and development.

Conference: "The future of Molecular Medicine: Imaging of human biology by Positron Emission Tomography?" - Prof. Bengt R. Langström - Brussels, 22 February 2012

Bengt LangstromProf. Langström, from the Department of Biochemistry and Organic Chemistry at the Uppsala University, Sweden, the Imperial College, London, UK and the Syddansk University, Odense, Denmark was invited by the NewTech Workgroup and Prof. Dewi M. Lewis to speak about the future of Molecular Medicine.
Molecular Imaging (MI) is interpreted as a technology to obtain images from a semantic view. However there are more relevant factors to consider in the image interpretation such as the half-life of the radio-nuclide, the way of producing the labelled compounds (the tracers), the design of the experimental and clinical protocols. With positron emission tomography (PET) an important feature is that we have access to other unique radio-nuclides 15O, 13N and 11C - opening up a road to apply endogenous molecules in numerous different applications.
For PET technology there has been considerable on-going development and a lot of exciting achievements made, however I would like to claim that so far we and the technology have underachieved and that there is much more to expect from these positron emission tracers (PET) and to make another semantic interpretation.
In the lecture there was a discussion on how to produce these labelled compounds, what technology is being used and what technology is still to be developed to exploit their molecular properties and to design new application protocols. There will be discussion on the consequences of these unique properties with reference to the high specific radioactivity and to the fate of the labelled molecules? Maybe the focus should be on the use of single or multi tracers in order to understand the biology? Are there other applications to utilize where there is a need of using the tracer concept not only to visualize but to quantify and to be able to be used in repetitive experiments where controlled modifications of the various tracer types can be applied?
One may argue that there is a need to get back to more basic research not only to label compounds but to develop further chemistry methods and more appropriate technology to meet the huge potential of PET. Maybe the most unique characteristics of PET are found in the fact that we have access to 15O, 13N and the pearl of the crown 11C. We have huge possibilities to develop, explore and validate many more tracers as tools in order to understand human biology There are many applications to diagnose, to stage, to treat, to follow up in drug development and the exploration of basic in vivo biochemistry. It is worth remembering that the radio-nuclides of key elements of life give us tools for in vivo biology dynamics studies.
The access to other labelled compounds using radio-nuclides with longer half-life such as 18F, and radio-metals like 68Ga, 64Cu attached to macromolecules like peptides and proteins shows other application areas where molecular imaging can be used to explore human biology.
There was a discussion on some of these issues and an argument that it is time to regain a wider perspective of MI for not only discussing and validating the images themselves but to understand better their content and the biological information that can be generated, by using MI technology in a wider perspective,
So more focus on quantification, on the molecular and experimental design however but without neglecting the resolution of MI as well as other MI modalities available – this is the lead for the future.

Conference: “European Perspectives in Personalised Medicine” – Brussels - EU Directorate for Reasearch & Innovation - 12-13 May 2011

The Health Directorate of the European Commission’s DG Research and Innovation organised the conference European Perspectives in Personalised Medicine, in Brussels on 12 -13 May 2011. The conference took place at the Square Meeting Centre, in the presence of John Dalli , Commissioner for Health and Consumer Policy, and with the support of Maire Geoghegan-Quinn, Commissioner for Research, Innovation and Science.

The conference aimed to take stock of recent achievements in health related research leading to personalised medicine and helped to identify and prioritise future actions needed at the European level. It brought together over 450 European and national level policy makers, industrial and academic researchers, patients, clinicians and other stakeholders.
On the initiative of Dr Philippe Jehenson, from the Health Directorate of the EU DG Research and Innovation AIPES was invited to partake in one of the discussion panels.
Thomas Beyer, Chair of the New Technologies Working Group, represented AIPES as a panelist in Session 2 on “Biomarkers in Personalized Medicine”. While most speakers at that conference described the "*omics" (incl. gene profiling) as the mainstay of personalized medicine, Thomas Beyer added a number of remarks on molecular imaging without which Personalized Medicine would not be possible. Thanks to Philippe Jehenson additional input on molecular imaging was provided to this conference through other speakers (e.g., Markus Schwaiger, Munich). It became clear that if AIPES intends to support nuclear medicine as an integral part of personalised diagnosis and treatment, then AIPES needs to be actively involved in these types of conferences more often.

Conference: "Molecular Imaging in Drug Discovery and Development: Challenges and Opportunities" - Prof. Dettlef Stiller Phd. - Brussels, 23 February 2011

Stiller FotoBrussels, 23rd February. On the initiative of the New Technologies Working Group, Dr Detlef Stiller gave a speech at the Conrad Hotel in front of more than 50 attendants – most of them being physicians, oncologists and nuclear medicine professionals. Since 2000, Dr Detlef Stiller has been the Head of the in vivo imaging unit at Boehringer Ingelheim Pharmaceuticals (Germany), with responsibility for the integration, assessment and validation of imaging technologies in drug discovery and development. After a short introduction by Thomas Beyer and Dewi Lewis, Dr Stiller highlighted the challenges and opportunities of molecular imaging in drug discovery and development.
In the past few decades, the remarkable advances in molecular biology and imaging has created a new emerging discipline, molecular imaging (MI) – allowing us to take a deeper and more precise look inside the human body, to distinguish smaller structures or monitor their activity. MI can facilitate Translational Medicine and lead to a better understanding of the pathogenesis of a disease – most notably by elucidating the behavior of many diseases and to study their response to certain drugs or therapies. It represents a tremendous asset to personalized medicine.
Despite very restrictive guidelines of the regulatory authorities for the development of new imaging agents, we now see that pharmaceutical industry, imaging device vendors, tracer developers and regulatory authorities have started to come together to address this challenge.

Konrade VBConference: "From Pharmaco-economics to Health Technology Assessment (HTA) - Can Radiopharmaceuticals be HTA compatible for Reimbursement?" - Dr Konrade von Bremen - Brussels, 17 February 2010

The challenge for any pharmaceutical industry is to obtain reimbursement from health insurance fees in a timely fashion. Different hurdles have been put in place before obtaining the full market recognition with adequate reimbursement. After clinical evidence, pharmaco-economic analysis became compulsory for submission to authorities. Health Technology Assessment is the current gold standard for a reimbursement dossier in most countries. Can Radiopharmaceuticals be HTA compatible ……………for reimbursement?
Dr Konrade von Bremen is CEO of the SWAN-Group (Bern, Switzerland), a Holding that aims at fostering technological advances in medicine through the set-up of a radiopharmaceutical production unit and distribution network as well as through the design, concept, planning and operation of a privately financed proton therapy center in Switzerland.
Dr von Bremen graduated from the Medical faculty at Siena (IT) in 1991. In 1998 she specialised in Internal Medicine in Switzerland. She received a Master degree in Health Economics and Management in 2000 from the University of Lausanne (CH) and a Certificate of Advanced Studies in the Management of Med-/Biotech and Pharma Ventures from the same university in 2009.
From 2000-20002 Dr von Bremen served as Associate Medical Director of the University Hospital Lausanne (CH), before joining MEDTRONIC in Tolochanz (CH ) as the Director Clinical of the Neuro-Division of in 2002. She holds various research and teaching appointments with Universities in Switzerland and Italy in the field of Health Technology Assessment and industry relations. In 2006 she was appointed Project Director of Innovation Projects at the Inselspital Bern.
Proven competencies of Dr von Bremen include the design and implementation of interdisciplinary innovation projects in the realms of academia and industry; the assessment of healthcare technologies and associated reimbursement strategies, the definition of multi-disciplinary training programmes, global healthcare management and system analysis in view of optimized organizations in hospitals and healthcare industry.